KYKamlesh Kumar Yadav

Kamlesh Kumar Yadav

*This is an algorithmically generated author record based on publicly available information.

Kamlesh Kumar Yadav has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epigenetic–Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer

    by Chandrima Das, Swagata Adhikari, Apoorva Bhattacharya, Sanjukta Chakraborty, Payel Mondal, Shalini S. Yadav, Santanu Adhikary, Clayton R. Hunt, Kamlesh K. Yadav, Shruti Pandita, et al.

    Therapy resistance is imposing a daunting challenge on effective clinical management of breast cancer. Although the development of resistance to drugs is multifaceted, reprogramming of energy metabolism pathways is emerging as a central but heterogenous regulator of this therapeutic challenge. Metabolic heterogeneity in cancer cells is intricately associated with alterations of different signaling networks and activation of DNA damage response pathways. Here we consider how the dynamic metabolic milieu of cancer cells regulates their DNA damage repair ability to ultimately contribute to development of therapy resistance. Diverse epigenetic regulators are crucial in remodeling the metabolic landscape of cancer. This epigenetic–metabolic interplay profoundly affects genomic stability of the cancer cells as well as their resistance to genotoxic therapies. These observations identify defining mechanisms of cancer epigenetics–metabolism–DNA repair axis that can be critical for devising novel, targeted therapeutic approaches that could sensitize cancer cells to conventional treatment strategies.


  • Open Access

    Development and validation of a polygenic hazard score for aggressive prostate cancer identification

    by Nihal E. Mohamed, Ashutosh K. Tewari, Kamlesh K. Yadav

    Development and validation of a polygenic hazard score for aggressive prostate cancer identification

    • 1 January 2019
      • Vol. 7  (4) , 262-+

    Predictive value of pseudouridine in prostate cancer

    by Jennifer A. Stocked, Akriti Gupta, Bryan Herzog, Shalini S. Yadav, Ashutosh K. Tewari, Kamlesh K. Yadav

    Background: Recent studies have shown that certain small nucleolar RNAs (H/ACA snoRNAs) and the protein dyskerin (DKC1) are upregulated in prostate cancer and are thought to contribute to progression of disease. These components convert uridine to pseudouridine (abbreviated psi), a type of post-transcriptional modification of RNA. Given the increased abundance of H/ACA snoRNAs and expression of DKC1 in prostate carcinomas, and because whole-body turnover of RNA increases in support of rapidly-growing cancer cells, we examined the value of pseudouridine as a biomarker for prostate cancer. Methods: Using a monoclonal antibody against pseudouridine, we tested its ability to distinguish between two 25-base RNA oligonucleotide sequences that differed by only one psi-substitution, and subsequently measured psi in RNA isolated from several prostate cancer cell lines representing different stages of disease using dot blot assays and pseudouridinylated RNA linked immunosorbent assay (PURLISA). We also performed immunohistochemistry on a tissue micro array (12 cases/24 cores) containing prostate adenocarcinomas and normal adjacent tissue (NAT). Results: High levels of pseudouridine were detected in androgen-independent cell lines (PC3 and Du145) compared to androgen-sensitive (LNCaP) and immortalized human prostate (RWPE) cells. Immunohistochemistry of a tissue micro array (TMA) containing normal adjacent and cancerous prostate tissue revealed a significant difference in immunoreactivity between normal and malignant tissue (P <= 0.0001). Conclusion: Our results provide new information on the relationship between pseudouridine expression and clinical progression of prostate cancer.


  • Open Access

    Epigenetic analysis identifies factors driving racial disparity in prostate cancer

    by Richa Rai, Shalini S. Yadav, Heng Pan, Irtaza Khan, James O'COnnor, Mohammed Alshalalfa, Elai Davicioni, Emanuela Taioli, Olivier Elemento, Ashutosh K. Tewari, et al.

    Background: Prostate cancer (PCa) is the second most leading cause of death in men worldwide. African‐American men (AA) represent more aggressive form of the disease compared to Caucasian (CA) counterparts. Several lines of evidences suggest that biological factors are responsible for the observed racial disparity.Aim: This study was aimed at identifying the epigenetic variation among AA and CA PCa patients and whether DNA methylation differences have an association with clinical outcomes in the two races.Methods and results: The cancer genome atlas (TCGA) dataset (2015) was used to identify existing epigenetic variation in AA and CA PCa patients. Reduced Representation Bisulfite Sequencing (RRBS) was performed to identify global DNA methylation changes in a small cohort of AA and CA PCa patients. The RRBS data were then used to identify survival and recurrence outcomes in AA and CA PCa patients using publicly available datasets. The TCGA data analysis revealed epigenetic heterogeneity, which could be categorized into four classes. AA associated primarily to methylation cluster 1 (p = 0.048), and CA associated to methylation cluster 3 (p = 0.000146). Enrichment of the Wnt signaling pathway was identified in both the races; however, they were differentially activated in terms of canonical and non‐canonical Wnt signaling. This was further validated using the Decipher Genomics Resource Information Database (GRID). The RRBS data also identified discrete methylation patterns in AA compared with CA and, in part, validated our TCGA findings. Survival analysis using the RRBS data suggested hypomethylated genes to be significantly associated with recurrence of PCa in CA (p = 6.07 × 10−6) as well as in AA (p = 0.0077).Conclusion: Overall, we observed epigenetic‐based racial disparity in PCa which could affect survival and should be considered during prognosis and treatment.


  • Top Cited Papers
    Open Access

    Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death

    by Haley Hieronymus, Rajmohan Murali, Amy Tin, Kamlesh Yadav, Wassim Abida, Henrik Moller, Daniel Berney, Howard Scher, Brett Carver, Peter Scardino, et al.

    The level of copy number alteration (CNA), termed CNA burden, in the tumor genome is associated with recurrence of primary prostate cancer. Whether CNA burden is associated with prostate cancer survival or outcomes in other cancers is unknown. We analyzed the CNA landscape of conservatively treated prostate cancer in a biopsy and transurethral resection cohort, reflecting an increasingly common treatment approach. We find that CNA burden is prognostic for cancer-specific death, independent of standard clinical prognosticators. More broadly, we find CNA burden is significantly associated with disease-free and overall survival in primary breast, endometrial, renal clear cell, thyroid, and colorectal cancer in TCGA cohorts. To assess clinical applicability, we validated these findings in an independent pan-cancer cohort of patients whose tumors were sequenced using a clinically-certified next generation sequencing assay (MSK-IMPACT), where prognostic value varied based on cancer type. This prognostic association was affected by incorporating tumor purity in some cohorts. Overall, CNA burden of primary and metastatic tumors is a prognostic factor, potentially modulated by sample purity and measurable by current clinical sequencing.


  • Intratumor heterogeneity in prostate cancer

    by Shalini S. Yadav, Jennifer A. Stockert, Victoria Hackert, Kamlesh K. Yadav, Ashutosh K. Tewari


  • Open Access

    Epigenetic analysis identifies factors driving racial disparity in prostate cancer

    by Richa Rai, Shalini S Yadav, Heng Pan, James O’connor, Mohamed Alshalalfa, Elai Davicioni, Emanuela Taioli, Olivier Elemento, Ashutosh K Tewari, Kamlesh K Yadav

    Prostate cancer (PCa) is the second most leading cause of death in men worldwide. African American men (AA) represent more aggressive form of PCa as compared to Caucasian (CA) counterparts. Evidence suggests that genetic and other biological factors could account for the observed racial disparity. We analyzed the cancer genome atlas (TCGA) dataset (2015) for existing epigenetic variation in AA and CA prostate cancer patients, and carried out Reduced Representation Bisulphite Sequencing (RRBS) analysis to identify global methylation changes in AA and CA prostate cancer patients. The TCGA dataset analysis revealed that the epigenetic heterogeneity could be categorized into 4 classes, where AA associated primarily to methylation cluster 1 (p value 0.048), and CA associated to methylation cluster 3 (p value 0.000146). We identified enrichment of Wnt signaling genes in both AA and CA, however they were differentially activated in terms of canonical and non-canonical Wnt signaling pathway activation. This was further validated using the GenomeDx expression data. Our RRBS data also suggested distinct methylation patterns in AA compared to CA, and in part validated our TCGA findings. Survival analysis using the RRBS data suggested hypomethylated genes to be significantly associated with recurrence of prostate cancer in CA (p=6.07×10 −6 ) as well as in AA (p=0.0077). Overall, the observed racial disparity in the molecular mechanism involved in the pathogenesis of prostate cancer suggests diverse heterogeneity that potentially could affect survival and should be considered during prognosis and treatment.

  • Open Access

    Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications

    by Shalini S. Yadav, Jinyi Li, Jennifer A. Stockert, Bryan Herzog, James O'COnnor, Luis Garzon-Manco, Ramon Parsons, Ashutosh K. Tewari, Kamlesh K. Yadav


  • MP87-09 DISTINCT EPIGENETIC AND TRANSCRIPTOMIC VARIATIONS IN AFRICAN AMERICAN MEN AS COMPARED TO CAUCASIAN IN PROSTATE CANCER

    by Richa Rai, Cordelia Elaiho, Victoria Hackert, Kamlesh K Yadav, Ashutosh Tewari, Shalini S Yadav

  • MP33-09 CLINICAL UTILITY OF PSEUDOURIDINE AS A DIAGNOSTIC MARKER TO DETECT PROSTATE CANCER

    by Jennifer Stockert, Shalini S Yadav, Ashutosh Tewari, Kamlesh K Yadav